VIR News and Press, Vir Biotechnology Inc. From 03/25/22

SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal...

Many years ago, it was decided that the definition of a "small cap" should be a company with a valuation under $2 billion. These days, with some mega caps having risen past the $2 trillion mark, we probably should move that benchmark a little. In this roundtable, three Fool contributors wer...

Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022. Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022. Results from the ...

A disagreement between Republican senators and the White House over funding for COVID-19 therapeutics and vaccines could imperil the Biden administration’s efforts to provide pandemic relief for Americans this year. The dispute stems from the level of transparency provided by the gover...

Vir Bio (NASDAQ: VIR) is one of the strongest buying opportunities I see in the market today. The company's COVID-19 treatment, Xevudy, works against the omicron variant. So the U.S. and other governments are spending a lot of money buying supplies of the drug, which runs about $2,0...

Baird has upgraded Vir Biotechnology (VIR +0.3%), the partner of GlaxoSmithKline (NYSE:GSK) in the development of COVID-19 therapy sotrovimab, to Neutral from Underperform, citing the recent decline in its shares. The team argues that after the recent weakness of company shares “market...

The Biden administration is planning to share U.S. government-devised COVID-19 technologies with the World Health Organization (WHO), The Washington Post reported Thursday, citing people familiar with the matter. However, the plan to be announced Thursday morning by Health and Human Services ...

SAN FRANCISCO, March 02, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in an infectious disease panel discussion at the 42 nd Annual Cowen Healthcare Conference on Wednesday, March 9, at 10:30 a.m. ET. The conferen...

Now is a great time to buy stocks. The market has been super-negative over the last couple of months. The war in the Ukraine and rising interest rates are two of the primary culprits, along with our COVID-19 malaise. This has made stocks a lot cheaper, and you can find some amazing bargains...

Vir Biotechnology (VIR -9.0%) the maker of COVID-19 antibody therapy sotrovimab is trading lower for the second consecutive session on Monday. Aside from the general weakness in the market, the recent decline in COVID-19 cases and hospitalizations appeared to have led to the recent selloff. &...